Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing

Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing

Multidrug resistance (MDR) represents a serious global threat due to the rapid global spread and limited antimicrobial options for treatment of difficult-to-treat (DTR) infections sustained by MDR pathogens. Recently, novel β-lactams/β-lactamase inhibitor combinations (βL-βLICs) have been developed...

Full description

Bibliographic Details
Main Authors: Paolo Gaibani, Tommaso Giani, Federica Bovo, Donatella Lombardo, Stefano Amadesi, Tiziana Lazzarotto, Marco Coppi, Gian Maria Rossolini, Simone Ambretti
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Antibiotics
Subjects:
novel β-lactams/β-lactamase inhibitors (βL-βLICs)
difficult-to-treat (DTR) pathogens
<i>Enterobacterales</i>
<i>P. aeruginosa</i>
<i>A. baumannii</i>
cross-resistance
Online Access:https://www.mdpi.com/2079-6382/11/5/628

Internet

https://www.mdpi.com/2079-6382/11/5/628

Similar Items